Helixmith Co., Ltd.
20
0
0
14
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 60/100
30.0%
6 terminated/withdrawn out of 20 trials
70.0%
-16.5% vs industry average
25%
5 trials in Phase 3/4
107%
15 of 14 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (20)
Safety and Efficacy Study of Engensis (VM202) in the Treatment of Chronic Non-Healing Foot Ulcers
Role: lead
Phase 3 Gene Therapy for Painful Diabetic Neuropathy
Role: lead
Study to Assess Safety and Efficacy of Engensis in Painful Diabetic Peripheral Neuropathy
Role: lead
Extension of Phase 3 Gene Therapy for Painful Diabetic Neuropathy
Role: lead
A 6-Month Extension Study of VMDN-003-2 to Assess Engensis in Participants With Painful Diabetic Peripheral Neuropathy
Role: lead
Safety Study of VM202 to Treat Amyotrophic Lateral Sclerosis
Role: lead
Safety Study of Gene Therapy in Treating Critical Leg Ischemia
Role: lead
Safety and Efficacy Study for the Treatment of Painful Diabetic Neuropathy
Role: lead
Gene Therapy for Painful Diabetic Neuropathy
Role: lead
A 6-Month Extension Study to Assess the Long-Term Safety of Engensis in Amyotrophic Lateral Sclerosis
Role: lead
Safety of Engensis in Participants With Amyotrophic Lateral Sclerosis
Role: lead
The Safety and Tolerability of Engensis (VM202) in Patients With Charcot-Marie-Tooth Disease Subtype 1A (CMT1A)
Role: lead
Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia
Role: lead
Safety Study of Gene Therapy for Ischemic Heart Disease in Korea
Role: lead
Gene Therapy for Chronic Granulomatous Disease in Korea
Role: lead
Gene Therapy for the Treatment of Chronic Stable Angina
Role: lead
Safety and Efficacy Study of Gene Therapy for Acute Myocardial Infarction in Korea
Role: lead
The Efficacy and Safety of TADIOS as an Adjuvant Therapy in Patients Diagnosed With Mild to Moderate COVID-19
Role: lead
Efficacy and Safety Study of PG201 Tablet in Patients With Osteoarthritis
Role: lead
Hepatocyte Growth Factor to Improve Functioning in PAD
Role: collaborator
All 20 trials loaded